A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
PURPOSE: The prognosis for locally advanced breast cancer (LABC) patients continues to be poor, with an estimated five-year survival of only 50-60%. Preclinical data demonstrates enhanced therapeutic efficacy with liposomal encapsulation of doxorubicin combined with hyperthermia (HT). Therefore this phase I/II study was designed to evaluate the safety and efficacy of a novel neoadjuvant combination treatment of paclitaxel, liposomal doxorubicin, and hyperthermia. MATERIALS AND METHODS: Eligible patients received four cycles of neoadjuvant liposomal doxorubicin (30-75 mg/m(2)), paclitaxel (100-175 mg/m(2)), and hyperthermia. They subsequently underwent either a modified radical mastectomy or lumpectomy with axillary node dissection followed by radiation therapy and then eight cycles of CMF (cyclophosphamide, methotrexate, 5-fluorouracil) chemotherapy. RESULTS: Forty-seven patients with stage IIB-III LABC were enrolled and 43 patients were evaluable. Fourteen patients (33%) had inflammatory breast cancer. Combined (partial + complete) clinical response rate was 72% and combined pathological response rate was 60%. Four patients achieved a pathologically complete response. Sixteen patients were eligible for breast-conserving surgery. The cumulative equivalent minutes (CEM 43) at T90 (tenth percentile of temperature distribution) was significantly greater for those with a pathological response. Four-year disease-free survival was 63% (95% CI, 46%-76%) and the four-year overall survival was 75% (95% CI, 58-86%). CONCLUSIONS: Neoadjuvant therapy using paclitaxel, liposomal doxorubicin and hyperthermia is a feasible and well tolerated treatment strategy in patients with LABC. The thermal dose parameter CEM 43 T90 was significantly correlated with attaining a pathological response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dressman, H. K., Hans, C., Bild, A., Olson, J. A., Rosen, E., Marcom, P. K., Liotcheva, V. B., Jones, E. L., Vujaskovic, Z., Marks, J., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1447 · Cited by 163 · cited 1×
“The results from the assessment of tumour pH and oxygenation, gene expression profile for response to treatment, MRI, MRS, and RPI imaging are reported elsewhere [24–26].”
BackgroundSelf-citation
Cited by
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
Zylberberg, C., & Matosevic, S. (2016) · Drug Delivery · doi:10.1080/10717544.2016.1177136 · Cited by 627
Strategies to improve the EPR effect: A mechanistic perspective and clinical translation
Ikeda-Imafuku, M., Wang, L. L.-W., Rodrigues, D., Shaha, S., Zhao, Z., & Mitragotri, S. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.043 · Cited by 330
Controlling the biodistribution and clearance of nanomedicines
Cabral, H., Li, J., Miyata, K., & Kataoka, K. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-023-00138-1 · Cited by 303
Landon, C. D. (2011) · The Open Nanomedicine Journal · doi:10.2174/1875933501103010038 · Cited by 281
Metadata
- Authors
- Vujaskovic, Z., Kim, D. W., Jones, E., Lan, L., Mccall, L., Dewhirst, M. W., Craciunescu, O., Stauffer, P., Liotcheva, V., Betof, A., & Blackwell, K.
- Venue
- International Journal of Hyperthermia
- Publisher
- Informa UK Limited
- Published
- 2010-04-08
- Volume
- 26
- Issue
- 5
- Pages
- 514-521
- ISSN
- 0265-6736 (ISSN-L)
- 1464-5157
- OpenAlex
- W1974817898
- Cited by
- 81
- References
- 1
- FWCI
- 2.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer. https://app.cochat.ai/papers/10.3109/02656731003639364
- The paper
- Vujaskovic, Z., Kim, D. W., Jones, E., Lan, L., Mccall, L., Dewhirst, M. W., Craciunescu, O., Stauffer, P., Liotcheva, V., Betof, A., & Blackwell, K. (2010). A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer. International Journal of Hyperthermia. https://doi.org/10.3109/02656731003639364
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.